Lexicon Pharmaceuticals Inc Investor Relations Material

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates comprise Sotagliflozin that completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes; and LX9211 which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech Inc.